secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269522
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q3 net loss $42.2M; shifts focus to type 1 diabetes and in vivo CAR T, suspends allogeneic CAR T
--------------------------------------------------------------------------------

- Q3 net loss $42.2M ($0.16/share); cash $153.1M; raised $115.8M in Q3, pro forma cash $170.5M.
- Prioritizing SC451 (type 1 diabetes) IND as early as 2026 and SG293 in vivo CAR T IND as early as 2027.
- Suspended allogeneic CAR T programs SC291 and SC262; NEJM published positive 12-week data for UP421 showing insulin production without immunosuppression.
- Non-GAAP operating cash burn $108M for 9 months; non-GAAP net loss $39M for Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/0001193125-25-269522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/sana-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer